This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Hemo Organic Q2 FY27 results, warrant conversion; auditor issues qualified opinion
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Hemo Organic Q2 FY27 revenue climbed to Rs 142.9 lakh from Rs 0.01 lakh a year ago. Quarterly loss narrowed to Rs 6.89 lakh from Rs 7.42 lakh. H1 operating cash flow was negative Rs 182.72 lakh. The company raised Rs 4.25 crore via preferential warrants in Feb 2026; all 34 lakh warrants were converted to equity shares on Sept 25. Proceeds were used for working capital and general corporate purposes with no deviation reported. Auditor issued a qualified review opinion citing missing balance confirmations for receivables and payables.
Higher revenue and smaller loss are positives, but the firm is still loss-making and burning cash. Auditor's qualified review is a concern for investors.
The company's XBRL figures for this quarter look filed in the wrong unit: revenue reads ₹1.43 Cr against ₹0.00 Cr a year ago, about 14,290× larger. A move that size is almost always a wrong unit, not a business, so nothing is computed from these figures and no number-based tags are set; the read above is the AI's, from the document.